Objective This study aimed to investigate the safety and efficacy of cadonilimab plus chemotherapy with or without bevacizumab in the treatment of recurrent or metastatic cervical cancer (R/M CC).

Methods A retrospective analysis was conducted on 25 patients with R/M CC who were admitted to Tianjin Medical University Cancer Institute & Hospital between August 2022 and June 2024. All patients received cadonilimab plus chemotherapy with or without bevacizumab, followed by cadonilimab as maintenance therapy. Treatment efficacy and adverse events were comprehensively evaluated, and patients were followed up until October 2024.

Results The median follow-up duration was 18 months (range: 4–26 months). The median progression-free survival (PFS) and overall survival were not reached, and the 1-year PFS rate was 77.9%. The objective response rate was 68%, while the disease control rate was 80%. Common adverse reactions included decreased white blood cell count (40%), nausea (32%), rash (24%), and anemia (24%). No treatment-related deaths occurred during the study period.

Conclusions Cadonilimab plus chemotherapy with or without bevacizumab demonstrated a high objective response rate and a favorable safety profile in patients with R/M CC. However, further studies with larger sample sizes and extended follow-up periods are needed to further validate these findings.